SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, Daniel Stadlbauer, Hala Alshammary, Angela A. Amoako, Mahmoud Awawda, Katherine F. Beach, Maria C. Bermúdez‐González, Rachel Chernet, Lily Eaker, Emily D. Ferreri, Daniel Floda, Charles Gleason, Giulio Kleiner, Denise Jurczyszak, Julia C. Matthews, Wanni A. Mendez, Lubbertus C. F. Mulder, Kayla T. Russo, Ashley-Beathrese T. Salimbangon, Miti Saksena, Amber S. Shin, Levy A. Sominsky, Komal Srivastava, Florian Krammer, Viviana Simon, Luis Martínez‐Sobrido, Adolfo García‐Sastre, Michael Schotsaert
Abstract
To evaluate the influence of a SARS-CoV-2 spike E484K mutation on the neutralizing activity of COVID-19 negative, convalescent and post vaccination sera.
Topics & Concepts
NeutralizationAntibodyPolyclonal antibodiesVirologyBiologyMolecular biologyGeneticsSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy research